OXFORD BIOMEDICA ORD 50P overview

Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30% Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmes FY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim Results FY2023 Preliminary Results to be...

Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK Expands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues 3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB)...

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors.. This event will demonstrate how unique and transferable technical...

Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing) On track to achieve 2023 guidance provided at the Interim Results and reiteration of medium term guidance; growth supported by new orders recently signed across lentivirus, adeno-associated virus (AAV) and adenoviral vectors Progress towards multi-vector multi-site model with transfer of lentiviral...

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe The transaction Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UK Expands Oxford Biomedica’s capacity in process and analytical...

Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform PR Newswire EMERYVILLE, Calif., Sept. 20, 2023 The non-exclusive, multi-year license and supply agreement enables use of LentiVector ® with any Kyverna product Agreement supports Kyverna's scalability and reliability of CAR T cell manufacturing goals EMERYVILLE, Calif. , Sept. 20, 2023 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of...

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect...

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023 Newly...